Tarsus Pharmaceuticals, Inc. TARS
NASDAQ · United States · Health Technology
$78.61+1.92 (+2.50%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California. The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY® (lotilaner ophthalmic solution) 0.25%; and the pr
Investor's Business Daily's IBD 50 index is on track for a third straight down month, and some of its components are sputtering. Various factors help decide when to sell stocks, and five have already triggered sell signals. AngloGold Ashanti broke out above a 113.30 buy point on Aug. 20.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus’ differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately hel
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.